Loading...
Cortexyme, Inc.
CRTX•NASDAQ
HealthcareBiotechnology
$1.95
$0.05(2.63%)
Cortexyme, Inc. (CRTX) Stock Overview
Explore Cortexyme, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for CRTXStats details for CRTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CRTXAnalyst Recommendations details for CRTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
CEO
Ms. Casey Lynch
Employees
55
Headquarters
269 E Grand Ave, South San Francisco, CALIFORNIA
Founded
2019